DE60327801D1 - Malaria-vakzine - Google Patents

Malaria-vakzine

Info

Publication number
DE60327801D1
DE60327801D1 DE60327801T DE60327801T DE60327801D1 DE 60327801 D1 DE60327801 D1 DE 60327801D1 DE 60327801 T DE60327801 T DE 60327801T DE 60327801 T DE60327801 T DE 60327801T DE 60327801 D1 DE60327801 D1 DE 60327801D1
Authority
DE
Germany
Prior art keywords
protein
hybrid
glutamate
antibody response
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60327801T
Other languages
English (en)
Inventor
Michael Theisen
Soeren Jepsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Statens Serum Institut SSI
Original Assignee
Statens Serum Institut SSI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Serum Institut SSI filed Critical Statens Serum Institut SSI
Application granted granted Critical
Publication of DE60327801D1 publication Critical patent/DE60327801D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60327801T 2002-11-12 2003-11-06 Malaria-vakzine Expired - Lifetime DE60327801D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK200201741A DK200201741A (da) 2002-11-12 2002-11-12 Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum
DKPA200301307 2003-09-11
PCT/DK2003/000759 WO2004043488A1 (en) 2002-11-12 2003-11-06 Malaria vaccine

Publications (1)

Publication Number Publication Date
DE60327801D1 true DE60327801D1 (de) 2009-07-09

Family

ID=32313776

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60327801T Expired - Lifetime DE60327801D1 (de) 2002-11-12 2003-11-06 Malaria-vakzine

Country Status (14)

Country Link
US (2) US7749507B2 (de)
EP (1) EP1567189B1 (de)
JP (1) JP4573773B2 (de)
CN (1) CN1741815B (de)
AT (1) ATE432081T1 (de)
AU (1) AU2003275949B2 (de)
BR (1) BR0315205A (de)
CA (1) CA2505724C (de)
DE (1) DE60327801D1 (de)
DK (2) DK200201741A (de)
ES (1) ES2326415T3 (de)
HK (1) HK1080754A1 (de)
WO (1) WO2004043488A1 (de)
ZA (1) ZA200504415B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030161840A1 (en) * 1992-10-19 2003-08-28 Institut Pasteur Plasmodium falciparum antigens inducing protective antibodies
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
DK200201741A (da) * 2002-11-12 2003-09-16 Statens Seruminstitut Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum
US20050112133A1 (en) * 2003-10-24 2005-05-26 Pierre Druilhe GLURP-MSP3 fusion protein, immunogenic compositions and malarial vaccines containing it
US7488489B2 (en) * 2004-08-03 2009-02-10 Institut Pasteur Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies
EP2818175B1 (de) * 2009-05-05 2018-11-21 Cadila Healthcare Limited Kombinierter Impfstoff gegen Masern und Malaria
BR112012001061B8 (pt) 2009-07-15 2021-05-25 Univ British Columbia glicosídeos 2,3-fluorados como inibidores de neuraminidase, seu método de preparação, composição farmacêutica que os compreende e embalagem comercial
EP2385107B1 (de) 2010-05-03 2016-08-24 Institut Pasteur Auf Lentivirusvektor basierende immunologische Verbindungen gegen Malaria
DK2763694T3 (en) * 2011-10-04 2018-04-16 Statens Seruminstitut Preparation of a cysteine-rich protein
US20140348870A1 (en) * 2011-11-30 2014-11-27 The Regents Of The University Of California Immunogenic plasmodium falciparum antigen compositions and uses thereof
CN102533677B (zh) * 2012-01-10 2013-07-24 特菲(天津)生物医药科技有限公司 一种疟疾疫苗及其制备方法
WO2013106937A1 (en) 2012-01-19 2013-07-25 The University Of British Columbia 3' equatorial-fluorine-substituted neuraminidase inhibitor compounds, compositions and methods for the use thereof as anti-virals
CN105652009B (zh) * 2014-11-11 2018-04-24 中国科学院苏州纳米技术与纳米仿生研究所 可用于辅助诊断疟疾的试剂盒
CN105628928A (zh) * 2014-11-11 2016-06-01 深圳国际旅行卫生保健中心 可用于辅助诊断疟疾的试剂盒
CA3031399A1 (en) * 2016-07-21 2018-01-25 Vac4All Pte. Ltd. Biofusion proteins as anti-malaria vaccines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231168A (en) * 1988-09-16 1993-07-27 Statens Seruminstitut Malaria antigen
DK519188D0 (da) * 1988-09-16 1988-09-16 Statens Seruminstitut Kemisk forbindelse
AU645482B2 (en) * 1988-09-16 1994-01-20 Statens Serum Institut A malaria antigen
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
CA2363118A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Immunogens comprising a peptide and a carrier derived from h.influenzae protein d
EP1390401A2 (de) * 2001-05-16 2004-02-25 Institut Pasteur Antigene von plasmodium falciparum und ihre verwendung als impfstoff und zur diagnose
DK200201741A (da) * 2002-11-12 2003-09-16 Statens Seruminstitut Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum

Also Published As

Publication number Publication date
JP2006512926A (ja) 2006-04-20
WO2004043488A1 (en) 2004-05-27
ZA200504415B (en) 2006-03-29
AU2003275949B2 (en) 2008-06-05
AU2003275949A1 (en) 2004-06-03
CN1741815A (zh) 2006-03-01
EP1567189B1 (de) 2009-05-27
BR0315205A (pt) 2005-08-16
DK200201741A (da) 2003-09-16
ATE432081T1 (de) 2009-06-15
US7749507B2 (en) 2010-07-06
JP4573773B2 (ja) 2010-11-04
EP1567189A1 (de) 2005-08-31
CN1741815B (zh) 2010-05-26
DK1567189T3 (da) 2009-09-14
CA2505724C (en) 2015-06-30
ES2326415T3 (es) 2009-10-09
US20110020387A1 (en) 2011-01-27
US20060024324A1 (en) 2006-02-02
CA2505724A1 (en) 2004-05-27
HK1080754A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
HK1080754A1 (en) Malaria vaccine
CY1114030T1 (el) Ομοιογενη παρασκευασματα toy il-29
IL214460A0 (en) Malaria prime/boost vaccines
ATE412433T1 (de) Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien
ATE309360T1 (de) Vaskularer endothelialer wachstumsfaktor 2
ATE454901T1 (de) Verfahren zur erhaltung zellimmuneantworten gegen proteinen
DE60232577D1 (de) Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
PT101052A (pt) Proteinas hibridas uteis na preparacao de vacinas
EP1490094A4 (de) Antikörper-fusionsproteine: wirksame adjuvantien bei der proteinvakzination
WO2003083058A3 (en) Replikin peptides in rapid replication of glioma cells and in influenza epidemics
ATE395930T1 (de) Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
ATE321859T1 (de) B2microglobulin fusionsproteine und varianten mit hoher affinität
GB0118532D0 (en) Materials and methods relating to improved vaccination strategies
ATE286536T1 (de) Bindungs domänen von plasmodium vivax und plasmodium falciparum erythrozyten-bindenden proteinen
WO2008086386A3 (en) Adenoviral vector-based malaria vaccines
EA201171347A1 (ru) Комбинированная вакцина против кори и малярии
WO2003062374A3 (en) Synthetic genes for malarial proteins and methods of use
ATE332380T1 (de) Materialen und verfahren mit bezug auf immunantworten gegen fusionsproteine
ATE448793T1 (de) Rekombinante hybrid-allergenkonstrukte mit verringerter allergenität unter beibehaltung der immunogenität des natürlichen allergens
ATE214097T1 (de) Die ansteckung blockierende malariaimpfstoffe
ATE139537T1 (de) Gen zum kodieren eines antigens gegen menschlichen malaria impfstoff
WO2004044167A3 (en) Expression, purification and uses of a plasmodium falciparum liver stage antigen 1 polypeptide
DE60216523D1 (de) Herstellung und verwendung von mit verzweigten aminosäuren angereicherten sojaproteinhydrolysaten
ITRM20010336A0 (it) Anticorpo umano ricombinante diretto contro la proteina non strutturale ns3 del virus dell'epatite c (hcv), acido nucleico codificante e usi
DE602006010061D1 (de) Malariaimpfstoffe

Legal Events

Date Code Title Description
8364 No opposition during term of opposition